About a year ago, I first published my "weed investors' bible," The Roadmap to Marijuana Millions. At the time, it was packed with 30 of my absolute favorite plays in the still-booming legal cannabis sector.
Since then, weed investing's only gotten bigger, better, and more profitable.
Over the past year, this section of the Nova-X Report portfolio has seen 10 double-digit winners and eight triple-digit winners... 291% gains... 193.3%... 189.5%; one recommendation even saw peak gains of 1,588%.
In other words, if you're a subscriber who jumped in when I released a recommendation, you've likely made a mint... and you've probably kept a mint, too, if you closely follow my recommended "free trade" strategy of taking your initial stake off the table and playing with the "house money" every time a stock hands out 100% gains.
Normally, I keep these high-profit recommendations close to the vest, for my paid-up Nova-X Report readers, but several times throughout 2017, the profit potential has been so juicy that I've released recommendations for Money Morning Members to participate in, too.
Now I want to let everyone in on what's coming just around the corner.
I'm expecting four watershed events in marijuana investing to happen over the next 365 days.
I'm going to show you exactly where I think the biggest profits of 2018 will come from in our "second season" of legal weed investing...
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Weed Investors: Get Ready
My team and I are putting the finishing touches on "Phase II" of the Roadmap to Marijuana Millions. It'll get Nova-X Report readers headed into the next year with the latest updated information on the best cannabis investments in biotech/pharma, recreational and medicinal retail, distribution, edibles, and more.
What's more, it'll have the latest word on the huge regulatory happenings at the state and federal levels that I believe will really enable pot stocks to take off (even more than they already have). Once the report's ready, my team will upload it to the "Research Reports" dashboard and let everyone know it's there.
I'm sharing these predictions with everyone today for the same reason I've shared some of my best weed investing recommendations: The profit potential is enormous.
And I want to make sure everyone has the chance to deploy their capital when these upcoming events come to pass. We're looking at some massively profitable outcomes here.
Pot Prediction No. 1: Full Legalization in California Will Be Earth-Shattering
I can't really overstate this one. On Jan. 1, 2018, the state of California will declare cannabis of all kinds fully legitimate. Make no mistake: This state's long-established medical marijuana market is already huge, accounting for about half of the total U.S. marijuana market, but when one of the world's six biggest economies takes recreational weed above board... watch out. The chains will be off. This landmark event will line the pockets of the legal weed companies - and their investors. I couldn't be more excited for this.
Pot Prediction No. 2: The Great Green North
Earlier this year, Canadian Prime Minister Justin Trudeau fulfilled a campaign promise to put forth a bill legalizing recreational marijuana throughout the entire country. The bill passed Canada's Parliament and was given royal assent by the Governor General. This cleared the way for July 2018, when the legal weed becomes, effectively, the law of the land, and Canada joins Uruguay as the only other country on the planet with total legalization. This is going to act like nothing less than rocket fuel for the five micro-cap Canadian weed plays we've picked up "on the cheap," and I expect it will catalyze round after round of gains in most, if not all, Canadian weed stocks. What's more, Canada (and Uruguay's) success with legal weed will serve as a model for other countries' pot plans, especially in Europe - and in several states here at home.
Pot Prediction No. 3: The Next 1,100% in Gains
We were early - very early - to pick up on the extreme profit potential of the world's first cannabis biotech, UK-based GW Pharmaceuticals Plc. This firm had the UK's first-ever license to grow pot for medical research purposes, and boy, did that "first-mover" status pay off. GW marketed the first cannabis-based medicine on the market, Sativex... and the rest is history. The company, previously traded only in London, listed shares on the American Nasdaq exchange and paid Money Morning Members who got in early quadruple-digit peak gains.
I'm expecting lightning to strike twice with GW Pharma, as the U.S. Food & Drug Administration (FDA) approves its newest cannabis-based therapy, Epidiolex, for use in the United States. There's nothing quite like an FDA approval to ignite a biotech stock. And it makes me confident in the future of other cannabis-based treatments from other pharma companies, too.
Pot Prediction No. 4: Crypto-Cannabis Goes Mainstream
I'm predicting that 2018 will see a major convergence of cryptocurrencies and legal cannabis. We're just starting to see the first glimmers of this happening now, and it's not quite ready for "prime time," but I see the year ahead shaping up to be one where cryptocurrencies and legal weed make some big mainstream gains... together.
Some Ethereum-based companies are already focusing their efforts on cannabis. Paragon Coin - a venture of weed guru and former Miss Iowa Jessica VerSteeg and hip-hop musician Jayceon Taylor (a.k.a. The Game) - is trying to build a blockchain-based "ecosystem" for the weed industry. Let me be clear: Many of these ventures will fail (I don't think investors should put their hopes in rappers and ex-beauty queens), and some will take millions of dollars along down the tubes for the ride but, significantly, the floodgates are open and the idea is out there. I'm totally confident that sometime in the next year, we'll see a convergent crypto-cannabis speculative investment worth jumping on.
Michael's going to make sure all of his paid-up Nova-X Report subscribers get the recommendations and research in his updated Roadmap to Marijuana Millions. He's expecting 2018's profits to top this year's biggest gains, so it'll be released shortly. Click here to learn how to get your copy.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.